SKL2001 is a novel agonist of Wnt/β-catenin pathway with anti-cancer activity. SKL2001 suppresses colon cancer spheroid growth through regulation of the E-cadherin/β-Catenin complex. SKL2001 inhibited proliferation of colon cancer cells cultured in 3D spheroid and induced them accumulation in the G0/G1 phase of the cell cycle with a reduced c-myc level. SKL2001 (5, 10, and 30 μM) stabilizes intracellular β-catenin in 3T3-L1 cells. SKL2001 (40 μM) significantly inhibits the proliferation of HCT116 spheroids independently of cytotoxicity and the inhibition is reversible.
Molecular Weight | 286.29 |
Formula | C14H14N4O3 |
CAS Number | 909089-13-0 |
Solubility (25°C) | DMSO ≥ 60 mg/mL |
Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related Wnt/beta-catenin Products |
---|
Fz7-21
Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. |
FZD7 antagonist 1
FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue. |
NLS-StAx-h
NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC50 of 1.4 μM. |
Zamaporvint
Zamaporvint is an orally active, selective Wnt inhibitor that targets the membrane-bound o-acyltransferase porcupine and inhibits Wnt ligand palmitoylation, secretion and pathway activation. In addition, Zamaporvint displays potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. It can be used in cancer-related studies. |
Foxy-5
Foxy-5, a WNT5A agonist and a mimetic peptide of WNT5A, triggers cytoplasmic free calcium signaling without affecting β-catenin activation and inhibits migration and invasion of epithelial cancer cells.Foxy-5 effectively reduces metastatic spread of prostate cancer cells with low WNT5A expression in an in situ mouse model. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.